Preclinical Testing of Metabolic Inhibitors with Erlotinib in Renal Medullary Carcinoma

Authors

• Daisha Lewis, The University of Texas MD Anderson Cancer CenterFollow
• Dalia Karimi, The University of Texas MD Anderson Cancer CenterFollow
• Pedro Pesquera, The University of Texas MD Anderson Cancer Center
• Tapati Maity, The University of Texas MD Anderson Cancer Center
• Manuel Ozambela, The University of Texas MD Anderson Cancer Center
• Pavlos Msaouel, The University of Texas MD Anderson Cancer Center
• Niki M. Zacharias, The University of Texas MD Anderson Cancer Center

Files

Program Affiliation

Partnership for Careers in Cancer Science and Medicine Summer Program

Recommended Citation

Lewis, Daisha; Karimi, Dalia; Pesquera, Pedro; Maity, Tapati; Ozambela, Manuel; Msaouel, Pavlos; and Zacharias, Niki M., "Preclinical Testing of Metabolic Inhibitors with Erlotinib in Renal Medullary Carcinoma" (2023). Summer Experience 2023. 94.
https://openworks.mdanderson.org/sumexp23/94

Keywords

RMC; Drug Assay; Erlotinib; Telaglenastat